Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
Metrics to compare | AELIS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAELISPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.2x | −2.3x | −0.5x | |
PEG Ratio | 0.05 | 0.05 | 0.00 | |
Price/Book | 1.7x | 2.1x | 2.6x | |
Price / LTM Sales | 3.0x | 10.2x | 3.0x | |
Upside (Analyst Target) | - | 199.2% | 54.7% | |
Fair Value Upside | Unlock | 7.4% | 8.4% | Unlock |